Bausch Health Companies에 대한 매도 수량은 투자자에게 Bausch Health Companies의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Bausch Health Companies (NYSE:BHC) 주식, 공매도 수량 보고

Bausch Health Companies

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Bausch Health Cos

investor charts ai2

Biotech

Long Ideas

Hedge Funds

Trading Ideas

General

BLCO

ILMN

JBLU

칼 아이칸은 실험실에서 활주로로 대담한 움직임을 보이고 있다. 그의 최신 13F 제출서에 따르면, 3월 31일로 끝나는 분기에 이 억만장자 행동주의 투자자는 일루미나(NASDAQ:ILMN) 및 제트블루 항공(NASDAQ:JBLU)에 대한 보유량을 크게 늘렸다 – 생명공학과 항공사 모두에 대한 인상적인 베팅이다.

칼 아이칸, 유전자와 항공기에 대한 베팅 강화: 일루미나 지분 450% 증가, 제트블루 보유 90% 증가

benzinga_deal_dispatch2

News

Markets

AMPS

BTBT

FYBR

LBPH

LSPD

MSGM

NVAX

PDCO

SNDR

TCEHY

UBSFF

USAP

새로이 등장한 블록 치과용품 제조업체인 패터슨 컴퍼니즈(NASDAQ:PDCO)가 주주 가치를 높이기 위해 매각 또는 합병을 포함한 전략적 옵션을 모색 중이라고 목요일 발표했다. 이 회사는 거래 과정을 2분기 재무 보고서의 일환으로 공개했다.

딜 디스패치: 유비소프트는 매각 협상 중, 패터슨은 매각 탐색 중, 프로마의 레카로 인수 등

Deal Dispatch

Asset Sales

PRPH

WOLF

뉴 온 더 블록 아리 엠마누엘(Ari Emanuel)의 스포츠 및 엔터테인먼트 대기업인 엔데버 그룹 홀딩스(NYSE:EDR)는 마이애미 오픈 및 마드리드 오픈 테니스 토너먼트를 포함한 IMG 테니스 자산 매각 가능성을 검토하고 있다. IMG의 다른 자산 대부분은 UFC(얼티밋 파이팅 챔피언십) 및 WWE(월드 레슬링 엔터테인먼트)의 모회사인 TKO 그룹 홀딩스(NYSE:TKO)와의 목요일에 발표된 거래에 포함되었다.

딜 디스패치: UFC, WWE 모회사 TKO가 불 라이딩 인수; 엔데버가 테니스 자산 매각 검토 등

Bausch Health Companies Inc. Common Stock

Bausch Health Companies Inc

BillionHappiness

BENCHMARK HLDGS PLC by Benchmark Hldgs PLC

Benchmark Holdings PLC

<a href="https://www.globenewswire.com/Tracker?data=NjIQv6kR4u-5jF8rBCclB-kIAf8osJ_pHaoa0lX7RsHypZRf7sCougOke6lBzNV3KWY9tnIpcTr7q8ZUi543FpymkEohGt4ySMmMbha9Bb4fYmKZP3GIGy-3mkx3xHqO">Outlook Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that LYTENAVA&#x2122; (bevacizumab gamma) is now commercially available in Germany and the UK for the treatment of wet age-related macular degeneration (wet AMD). LYTENAVA&#x2122; (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the European Union and UK.

OTLK

Outlook Therapeutics Launches First-Ever Eye Drug Bevacizumab for Wet AMD in Germany and UK

Guardant Health Announced That The Results Of The Phase III SERENA-6 Trial - Sponsored By Astrazeneca - Demonstrate The Clinical Value Of The Guardant360 Cdx Test In A Circulating Tumor DNA-guided Approach To Detect And Treat Emerging Resistance In 1St-line Therapy Ahead Of Radiological Disease Progression In Breast Cancer

–Attack progression halted in median 19.8 minutes after treatment with sebetralstat in both KONFIDENT and KONFIDENT-S trials–
–Sebetralstat data demonstrated rapid relief and resolution of severe HAE attacks–
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.kalvista.com%2F&amp;esheet=54263164&amp;newsitemid=20250602100361&amp;lan=en-US&amp;anchor=KalVista+Pharmaceuticals&amp;index=1&amp;md5=b60b173695655aa779d872d069a426bb">KalVista Pharmaceuticals</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) today announced new sebetralstat findings related to time to end of progression of hereditary angioedema (HAE) attacks, and the effectiveness of treatment of attacks considered the most debilitating by patients, mucosal attacks, and attacks that have progressed in severity after a treatment delay. These data were presented at two congresses taking place concurrently: the 14th C1-inhibitor Deficiency &amp; Angioedema Workshop in Budapest, Hungary, and the Eastern Allergy Conference (EAC) in Palm Beach, Florida, from May 29–June 1, 2025.

KALV

KalVista Announces New Sebetralstat Data On HAE Attack Progression at Key Conferences

<ul>
<li>STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions</li>
<li>Nurix to receive a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount received by Nurix under this collaboration to date to $127 million</li>
<li>Nurix is eligible for an additional $465 million in development, regulatory and commercial milestones associated with the STAT6 program as well as potential future royalties and retains an option to co-develop and co-promote in the U.S.</li>
</ul>

Health Care

NRIX

Sanofi Has Exercised Its Option To Exclusively License Nurix Therapeutics' STAT6 Program, Including The Drug Development Candidate NX-3911, Nurix To Receive A $15M License Extension Fee From Sanofi Under Its 2019 Collaboration Agreement

Cyngn (the "Company" or "Cyngn") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) today announced the launch of the Cyngn Dealer Portal, an online resource hub created to support its growing dealer network. The portal provides easy access to a comprehensive suite of Cyngn assets, including sales materials, detailed pricing information, and co-marketing resources. This new tool will allow dealers to effectively present Cyngn's autonomous solutions to their customers, increasing efficiency and facilitating faster sales cycles.
 &nbsp;

Cyngn Launches Dealer Portal to Speed Up Sales of Its Autonomous Vehicle Tech

<ul>
<li>– Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms –</li>
<li>– Generally well-tolerated with low rates of adverse events and discontinuation –</li>
<li>– Brilaroxazine improved multiple neuroinflammatory markers reported to enhance efficacy and mitigate side effects –</li>
</ul>

RVPH

Reviva's Brilaroxazine Shows Broad, Durable Efficacy And Low Discontinuation In 1-Year RECOVER Phase 3 Extension Study

REGN

Regeneron Pharmaceutical Announced A Strategic In-licensing Agreement With Hansoh Pharmaceuticals Group Company Limited To Acquire Exclusive Clinical Development And Commercial Rights Outside Of The Chinese Mainland, Hong Kong And Macau For A Dual Glp-1/GIP Receptor Agonist Currently In Phase 3 Testing

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) with a Buy and raises the price target from $85 to $90.

Price Target

Analyst Ratings

VRNA

HC Wainwright & Co. Maintains Buy on Verona Pharma, Raises Price Target to $90

– Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI&#xAE; (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles –
DUBLIN, June 2, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439097-1&amp;h=841886729&amp;u=https%3A%2F%2Fwww.alkermes.com%2F&amp;a=Alkermes+plc">Alkermes plc</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) today announced the presentation of accepted research at key scientific conferences this spring, including presentations largely related to its psychiatry products LYBALVI&#xAE; (olanzapine and samidorphan) and ARISTADA&#xAE; (aripiprazole lauroxil). Several of these meetings coincided with Mental Health Awareness Month in May, an important moment to raise awareness about mental health conditions, support the millions of people living with these complex diseases, and acknowledge the critical work of healthcare providers. The meetings included:
<ul>
<li>American Association of Psychiatric Pharmacists (AAPP) Annual Meeting, April 27-30, Salt Lake City</li>
<li>The Neuroscience Education Institute (NEI) Spring Congress, May 8-10, Philadelphia</li>
<li>The Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Conference, May 13-16, Montreal</li>
<li>American Psychiatric Association (APA), May 17-21, Los Angeles</li>
<li>American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, May 27-30, Scottsdale</li>
<li>Psych Congress Elevate, May 28-31, Las Vegas</li>
</ul>

ALKS

Alkermes Highlights LYBALVI And ARISTADA Data At Key Scientific Conferences

<ul>
<li>ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078).</li>
<li>ENLIGHTEN 2 trial also showed statistically significant improvement in key secondary endpoints in the full population of 3CS at 24 weeks (p=0.0209) and SNOT-22 score at 24 weeks (p=0.0101).</li>
<li>Additionally, in pooled data from ENLIGHTEN 2 and ENLIGHTEN 1 trials in 64 CRS patients with nasal polyps, LYR-210 demonstrated a consistent positive trend over 24 weeks in multiple key efficacy endpoints.</li>
<li>Lyra plans to review the totality of the dataset from the ENLIGHTEN trials to evaluate next steps for pursuing an indication in non-polyp patients, as well as to continue development of LYR-210 in patients with nasal polyps&nbsp;&nbsp;</li>
</ul>

LYRA

Lyra Therapeutics' ENLIGHTEN 2 Phase 3 Trial Of LYR-210 For Chronic Rhinosinusitis Met Its Primary Endpoint, With LYR-210 Demonstrating Statistically Significant Improvement Compared To Sham Control In A Composite Of The Three Cardinal Symptoms

Keybanc analyst Christopher Carril initiates coverage on Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) with a Sector Weight rating.

Initiation

SHAK

Keybanc Initiates Coverage On Shake Shack with Sector Weight Rating

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4438958-1&amp;h=1951662543&amp;u=https%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc.">Anixa Biosciences, Inc.</a> ("Anixa" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of enrollment in the Phase 1 clinical trial of its breast cancer vaccine. This novel vaccine, invented at Cleveland Clinic, is also being developed in partnership with Cleveland Clinic and the Phase 1 trial is fully funded by a grant from the U.S. Department of Defense (DoD).
The vaccine is designed to stimulate the immune system to target breast cancer before it can recur or develop. A total of 35 women have received the vaccine in the trial, including 26 in the triple-negative breast cancer ("TNBC") group, four in the prevention group, and five in the pembrolizumab group. These participants represent three distinct patient cohorts:
<ul>
<li>TNBC Group: Women who have completed treatment for triple-negative breast cancer, are currently cancer-free, and are at risk of recurrence.</li>
<li>Prevention Group: Women who are cancer-free but carry genetic mutations that place them at high risk of developing breast cancer and have elected to undergo preventative mastectomy to lower their risk.</li>
<li>Pembrolizumab (Keytruda) Group: Women who are receiving pembrolizumab in a post-operative setting. These women are receiving the vaccine concurrently with pembrolizumab.</li>
</ul>
The final patient visits are scheduled for August 2025. Once completed, the final study report will be submitted to the Department of Defense. A Clinical Study Report (CSR) will then be prepared for submission to the U.S. Food and Drug Administration. As part of the continued development process, the Investigational New Drug (IND) application will be transferred from Cleveland Clinic to Anixa.
Anixa and Cleveland Clinic plan to submit for presentation all trial data at a major upcoming scientific meeting.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, commented, "We are very encouraged by the data we are seeing from this trial. Preliminary results show that our breast cancer vaccine is well tolerated, with more than 70% of patients demonstrating protocol-defined immune responses. These encouraging findings are guiding our planning for Phase 2 trials, which will include discussions with the FDA, protocol development, manufacturing, and clinical site selection. While cancer vaccines have traditionally faced significant hurdles, our approach is aimed at a novel target that has not been previously explored in this context. We believe this could represent a new paradigm in immuno-oncology. The breast cancer market, particularly for triple-negative breast cancer and genetically high-risk populations, continues to face a major unmet need. Our vaccine may offer a unique, immunologic pathway for both prevention and treatment."

ANIX

Anixa Biosciences Completes Enrollment In Phase 1 Clinical Trial Of Breast Cancer Vaccine

Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer
Data continue to support planned initiation of pivotal study in mid-2025
Next-generation triplet combinations with atirmociclib (CDK4-selective) &amp; ribociclib ongoing
CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Q0gTYYh0XNKiOiXKmI9gOsksgI8_wm3UouToi--Ehs1OVKagdDy56xsgmUueh0KPLXKLq3UXdZWqkn1HfkN7zoYBDDMyYEFAEORjJWyVHIQ=">Relay Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced updated interim clinical data for RLY-2608, the first known investigational allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα. The updated data have a median duration of follow-up of 12.5 months and remain consistent with data shared in December 2024. They show a median progression free survival (PFS) of 11.0 months in second line (2L) patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer who received RLY-2608 600mg twice daily (BID) + fulvestrant. These data are being presented today at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting.

RLAY

Relay Therapeutics Says Updated Interim Clinical Data For RLY-2608 Remain Consistent, Showing 10.3-Month Median PFS Overall And 11.0-Month Median PFS In 2L Patients With PI3Kα-Mutated, HR+/HER2- Metastatic Breast Cancer

Paul Buchheit, the engineer behind Gmail, once challenged the popular wisdom in tech product development with an essay where he argued that a "great" product needs to do only a few things very well.
What Happened: In a 2010 blog <a href="https://paulbuchheit.blogspot.com/2010/02/if-your-product-is-great-it-doesnt-need.html?utm_source=www.founderstribune.org&amp;utm_medium=referral&amp;utm_campaign=if-your-product-is-great-it-doesn-t-need-to-be-good-by-paul-buchheit">post</a>, Buchheit discussed the common criticism of the first iPad, noting that the backlash echoed early responses to the iPod.
"The negative responses are so perfectly misguided that it would be wrong to waste this opportunity," he wrote. He referred to a now-famous Slashdot review of the iPod that read: "No wireless. Less space than a nomad. Lame." Similar critiques of the iPad focused on what it did not have rather than what it did well.
Buchheit wrote that successful products didn't win by piling on features. "Those missing features are typically available in a variety of unsuccessful competing products," he wrote.
He illustrated his point by citing Gmail's stripped-down launch: "It was fast, stored all of your email (back when 4MB quotas were the norm), and had an innovative interface based on conversations and search."
He recalled that even the address book, a feature many considered fundamental, was built in just two days. "The engineer doing the work originally wanted to spend five days on it, but I talked him down to two since I never use that feature anyway," he noted.
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/45714138/vinod-khosla-tells-google-forget-about-search-sun-microsystems-co-founder-urges-tech-giant-to-invest-tens-of-billions-in-self-driving-before-others-catch-up">Vinod Khosla Tells Google Forget About Search, Sun Microsystems Co-Founder Urges Tech Giant To Invest &#8216;Tens Of Billions&#8217; In Self-Driving Before Others Catch Up</a>
Why It Matters: Buchheit articulated his belief that the "more features = better" mindset led otherwise smart people to build bad products.
"If a MacBook with OSX and no keyboard were really the right product, then Microsoft would have already succeeded with their tablet computer years ago," he observed. Instead, he urged creators to narrow their focus and execute well: "Pick three key attributes or features, get those things very, very right, and then forget about everything else."
"If your product needs ‘everything' in order to be good, then it&#8217;s probably not very innovative," he warned. "Put another way, if your product is great, it doesn&#8217;t need to be good." In his view, solid products succeeded not by being exhaustive, but by excelling at the essentials.
Despite Buchheit's references to Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) products, his speedy approach seems to contrast the company's visionary co-founder <a href="https://www.benzinga.com/general/24/04/38403093/steve-jobs-spent-hour-after-hour-on-product-design-he-cared-about-god-being-in-the-details-says-walt">Steve Jobs' process of dedicating "hour after hour" to product design.</a>
Earlier this year, Microsoft Corp. Co-founder <a href="https://www.benzinga.com/tech/25/02/43577868/bill-gates-says-steve-jobs-once-told-him-i-wish-youd-take-acid-that-would-enhance-microsofts-product-design-more-i-envy-those-skills-im-not-in-his-league">Bill Gates even shared an anecdote</a> about how Jobs suggested that he do hallucinogenic drugs to have &#8220;more taste&#8221; when designing Microsoft products.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/topics/25/06/45712700/apples-ai-struggles-to-keep-pace-with-rivals-ahead-of-wwdc-2025">Apple&#8217;s AI Struggles To Keep Pace With Rivals Ahead Of WWDC 2025</a></li>
</ul>
Photo courtesy: Koshiro K / Shutterstock.com

Tech

AAPL

MSFT

'If Your Product Is Great, It Doesn't Need To Be Good:' When Gmail Creator Paul Buchheit Took Aim At Tech's Obsession With Features

Retirees who have defaulted on their student loans may see a reduction in their Social Security checks from June. This is a result of&nbsp;the U.S. Department of Education&#8217;s decision to recommence involuntary collections on defaulted student loans, including garnishing wages, intercepting tax refunds and seizing a portion of Social Security benefits.
What Happened: The U.S. Department of Education is set to recommence collection activity on the nation&#8217;s $1.6 trillion student loan portfolio, after a nearly five-year pause due to Covid-era policies. According to the <a href="https://www.cnbc.com/2025/06/01/social-security-checks-student-loan-garnishments-begin.html">CNBC</a> report, the garnishments will start in June and the affected retirees may receive reduced Social Security checks from this month onwards.
As per Forbes, several retirees could see their monthly Social Security checks reduced significantly, in some cases down to just $750. However, the actual reduction will depend on factors such as the recipient&#8217;s birth date and when they began receiving benefits.
However, according to&nbsp;Nancy Nierman, assistant director of&nbsp;the Education Debt Consumer Assistance&nbsp;Program in New York, borrowers have options to halt these payment offsets.
Higher education expert Mark Kantrowitz states that federal student loan borrowers should have been given at least 30 days' notice before their Social Security benefits were offset. He notes that borrowers can avoid or halt the offset by proving financial hardship or having a pending loan discharge.
Meanwhile, Betsy Mayotte, president of&nbsp;The Institute of Student Loan Advisors, suggests that opting for an income-driven repayment plan could be a way out. Borrowers with severe, permanent mental or physical disabilities that prevent them from working may qualify for a Total and Permanent Disability (TPD) discharge, using proof from a doctor, the SSA, or the VA, suggest experts. 
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/economic-data/25/06/45715685/howard-lutnick-calls-1-2-trillion-trade-deficit-a-national-emergency-says-trumps-tariffs-are-not-going-away" target="_blank" rel="noreferrer noopener">Howard Lutnick Calls $1.2 Trillion Trade Deficit A &#8216;National Emergency,&#8217; Says Trump&#8217;s Tariffs Are &#8216;Not Going Away&#8217; &#8211; Benzinga</a>
Why It Matters: The resumption of involuntary collections on defaulted student loans is part of a broader trend of financial challenges facing retirees. The Consumer Financial Protection Bureau estimates that over&nbsp;450,000 federal student loan borrowers&nbsp;aged 62 and older may be impacted by this change. 
Furthermore, the resumption of student loan payments has had a significant impact on borrowers, with some seeing steep drops in their credit scores. This has created additional financial strain for retirees who are already facing the prospect of reduced Social Security benefits.
As retirees navigate these financial challenges, it&#8217;s important for them to explore all available resources, including charitable organizations that assist with health-care costs and food assistance programs. Additionally, retirees facing garnishments on their Social Security benefits&nbsp;may be able to prevent&nbsp;or stop the offset by proving a financial hardship or pursuing a discharge with their student loan servicer.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/news/politics/25/06/45716383/trump-administration-shuts-down-66-million-food-stamp-fraud-and-bribery-scheme-arrests-usda-employee-and-5-others" target="_blank" rel="noreferrer noopener">Trump Administration Shuts Down A $66 Million Food Stamp Fraud And Bribery Scheme, Arrests USDA Employee And 5 Others &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Personal Finance

June Social Security Checks Could Drop Sharply Due To Student Loan Garnishments — Experts Share Ways To Get Relief

ACRS

Aclaris Therapeutics Has Initiated A Randomized, Double-blind, Placebo-Controlled Phase 2 Trial Of Bosakitug (ATI-045) For Moderate-to-severe Atopic Dermatitis, Top Line Results Expected In The Second Half Of 2026

Guidance

SAIC

Science Applications Intl Affirms FY2026 Adj EPS Guidance of $9.10-$9.30 vs $10.24 Est; Affirms FY2026 Sales Guidance of $7.60B-$7.75B vs $7.93B Est

Earnings

Earnings Beats

Earnings Misses

Science Applications Intl Q1 Adj. EPS $1.92 Misses $2.22 Estimate, Sales $1.88B Beat $1.87B Estimate

Raymond James analyst Frank Louthan downgrades Rackspace Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) from Outperform to Market Perform.

Downgrades

Raymond James Downgrades Rackspace Technology to Market Perform

KYMR

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

Press Releases

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris

Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program

Bausch Health Announces Adoption of Shareholder Rights Plan

Legal

U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich

Bausch Health Announces Filing of Supplement to Proxy Statement

Bausch Health Announces Launch of Solta Medical's Fraxel FTX(TM)

Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System

Bausch Health Announces First Quarter 2025 Results

Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization

Comments

Bausch Health Companies

매도 수량

Bausch Health Companies (NYSE:BHC) 주식, 공매도 수량 보고

뉴스

파트너 / 기고자

벤징가 글로벌